Abstract:As a prototypical member of the IL-17 family, interleukin-17A (IL-17A) has received increasing attentions for its potent proinflammatory role as well as potential to be a key therapeutic target in human autoimmune inflammatory diseases; however, its roles in other pathological scenarios like neuroinflammations are not fully elucidated yet but appear essentially correlating and promising. Glaucoma is the leading cause of irreversible blindness with complicated pathogenesis still to be understood, where neuroinflammation was reported to be critically involved in its both initiation and progression. Whether IL-17A takes part in the pathogenesis of glaucoma through interfering neuroinflammation due to its potent proinflammatory effect is still unknown. In the present study, we investigated the role of IL-17A in the pathological process of glaucoma neuropathy as well as its relationship with the predominant immune inflammation mediator microglia in retina, trying to elucidate the underlying mechanisms from the view of inflammation modulation. In our study, RNA sequencing was performed for the retinas of chronic ocular hypertension (COH) and control mice. Western blot, RT-PCR, immunofluorescence, and ELISA were used to evaluate the microglial activation and proinflammatory cytokines release at conditioned levels of IL-17A, along with assessment of optic nerve integrity including retinal ganglion cells (RGCs) counting, axonal neurofilament quantification, and flash visual-evoked potential (F-VEP) examination. And the possibly involved signaling pathways were screened out to go through further validation in scenarios with conditioned IL-17A. Subsequently, IL-17A was found to be significantly upregulated in COH retina. Furthermore, suppression of IL-17A effectively diminished the loss of RGCs, improved axonal quality, and F-VEP performance in COH mice. Mechanistically, IL-17A promoted microglial activation and proinflammatory cytokines release along with enhanced phenotypic conversion of activated microglia to M2-type in early stage and to M1-type in late stage in glaucomatous retinas. Microglia elimination decreased the proinflammatory factors secretion, enhanced the RGCs survival and axonal quality mediated by IL-17A. Furthermore, IL-17A-induced the overactivation of microglia in glaucomatous condition was alleviated after blocking the p38 MAPK pathway. Taken together, IL-17A is involved in the regulation of retinal immune response and RGCs cell death in experimental glaucoma by essentially promoting retinal microglial activation via p38 MAPK signaling pathway. IL-17A dynamically regulates the phenotypic conversion of retinal microglia in experimental glaucoma partly depending on the duration of elevated intraocular pressure. Suppression of IL-17A contributes to alleviate glaucoma neuropathy and exhibits promising potential as an innovative target for therapeutic strategy in glaucoma.

MicroRNA-146a-5p protects retinal ganglion cells through reducing neuroinflammation in experimental glaucoma

MicroRNA-21 and Microrna-146A Negatively Regulate the Secondary Inflammatory Response of Microglia after Intracerebral Hemorrhage

The Effect of A2AReceptor Antagonist on Microglial Activation in Experimental Glaucoma

MicroRNA‐141‐3p inhibits retinal neovascularization and retinal ganglion cell apoptosis in glaucoma mice through the inactivation of Docking protein 5‐dependent mitogen‐activated protein kinase signaling pathway

Neuroprotective Effects of Overexpressed Microrna-200A on Activation of Glaucoma-Related Retinal Glial Cells and Apoptosis of Ganglion Cells Via Downregulating FGF7-mediated MAPK Signaling Pathway.

MicroRNA-93/STAT3 signalling pathway mediates retinal microglial activation and protects retinal ganglion cells in an acute ocular hypertension model

miR-196b-5p regulates inflammatory process and migration via targeting Nras in trabecular meshwork cells

Interplay between Müller cells and microglia aggravates retinal inflammatory response in experimental glaucoma

Interleukin-17A Modulates Retinal Inflammation by Regulating Microglial Activation Via the P38 MAPK Pathway in Experimental Glaucoma Neuropathy

MicroRNA regulation in an animal model of acute ocular hypertension.

COG1410 Regulates Microglial States and Protects Retinal Ganglion Cells in Retinal Ischemia-Reperfusion Injury.

Mesenchymal stem cell-derived extracellular vesicles protect retina in a mouse model of retinitis pigmentosa by anti-inflammation through miR-146a-Nr4a3 axis

MiR-146a Ameliorates Hemoglobin-Induced Microglial Inflammatory Response Via TLR4/IRAK1/TRAF6 Associated Pathways

Neuroprotection of the P2X7 receptor antagonist A740003 on retinal ganglion cells in experimental glaucoma

Involvement of microglia in early axoglial alterations of the optic nerve induced by experimental glaucoma

Decreased Mir-187 Induces Retinal Ganglion Cell Apoptosis Through Upregulating SMAD7 in Glaucoma.

Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa

Silencing microRNA‐29b‐3p expression protects human trabecular meshwork cells against oxidative injury via upregulation of RNF138 to activate the ERK pathway

Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury

Microrna-21A-5p/pdcd4 Axis Regulates Mesenchymal Stem Cell-Induced Neuroprotection in Acute Glaucoma.

Molecular Signaling from Microglia Impacts Macroglia Autophagy and Neurons Survival in Glaucoma